ClinicalTrials.gov
public full text
Public Domain
Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously untreated, locally advanced or metastatic, unresectable soft tissue sarcoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effectiveness of Systemic Treatments in Patients with Unresectable, Advanced, or Recurrent Soft Tissue Sarcomas Previously Treated with Anthracycline-Based Therapy: A Systematic Review and Network Meta-Analysis#298235
- Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma#1171157
- A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma#1033314
- Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas#803541
- Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma#967733
Record · ID 876315
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive